Size Matters to Industry

Large molecules are more likely to make it to market these days than small molecules, according to new reports.

By | April 11, 2012

Steve Snodgrass" > Flickr, Steve Snodgrass

FLICKR, STEVE SNODGRASS

A number of recent reports are highlighting the fact that the pharmaceutical industry is solidly moving in favor of the large molecule drugs known as biologics.  Although they are more difficult to make than small molecule compounds, they are also more difficult to reproduce generically, which may give companies a longer market advantage than for small molecule drugs.

Companies are making biologics a bigger part of their drug portfolios, with patent filings for this class of drugs increasing even while the overall patent numbers have gone down in recent years, according to a recent report by the law firm Withers & Rogers.  Another study by the biopharma consultancy company KMR Group showed that large molecule drugs also have a better chance of winning approval from the US Food and Drug Administration than small molecule products.

Why are small molecules getting short shrift? “It may be that large molecule development, in general, is more targeted ,” Joseph DiMasi, director of economic analysis for Tufts Center for the Study of Drug Development, told Genetic Engineering & Biotechnology News. As a result, he said, their “safety issues may be less prevalent.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech